An Overview of the Current Literature

Francesco Claps,Arianna Biasatti,Luca Di Gianfrancesco,Luca Ongaro,Gianluca Giannarini,Nicola Pavan,Antonio Amodeo,Alchiede Simonato,Alessandro Crestani,Alessia Cimadamore,Rodolfo Hurle,Laura S. Mertens,Bas W. G. van Rhijn,Angelo Porreca

DOI: https://doi.org/10.3390/jcm13154349

IF: 3.9

2024-07-26

Journal of Clinical Medicine

Abstract:Bladder cancer (BC) is the tenth most commonly diagnosed malignancy worldwide. In approximately 25% of cases, it presents as a muscle-invasive disease, requiring a radical treatment. Traditionally, the mainstay of treatment has been radical cystectomy (RC), but in the last decade, bladder-sparing treatments have been gaining growing interest. In particular, trimodal therapy (TMT) seems to yield survival results comparable to RC with less morbidity and better quality of life (QoL) outcomes. In this scenario, we aimed at shedding light on the role of the histological subtypes (HS) of BC and their prognostic significance in muscle-invasive BC (MIBC), treated either surgically or with TMT. We performed a narrative review to provide an overview of the current literature on this topic. When compared with patients diagnosed with conventional urothelial carcinoma (UC) of the same disease stage, survival did not appear to be significantly worse across the reports. But when sub-analyzed for separate subtype, some appeared to be independently associated with adverse survival outcomes such as the micropapillary, plasmacytoid, small-cell, and sarcomatoid subtypes, whereas others did not. Moreover, the optimal management remains to be defined, also depending on the therapeutic susceptibility of each histology. From this perspective, multi-disciplinary assessment alongside the routine inclusion of such entities in randomized clinical trials appears to be essential.

medicine, general & internal